Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mutlu Doğan

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Cancer Investigation|May 20, 2021
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World ExperienceAykut Bahçeci, Semra Paydaş, Naziye Ak, et al.
Turkish Journal of Medical Sciences|November 3, 2022
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)Cihan Erol, Abdullah Sakin, Tuğba Başoğlu, et al.
BMC Cancer|February 11, 2023
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyCengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Cancer Investigation|May 20, 2021
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World ExperienceAykut Bahçeci, Semra Paydaş, Naziye Ak, et al.
Turkish Journal of Medical Sciences|November 3, 2022
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)Cihan Erol, Abdullah Sakin, Tuğba Başoğlu, et al.
BMC Cancer|February 11, 2023
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyCengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, et al.
Pageof 3